Annual Report 2023
Department for The Promotion of Drug and Diagnostic Development
Division of Drug and Diagnostic Development Promotion
Translational Research Support Office
Hideaki Bando, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Tadayoshi Hashimoto, Taro Shibuki, Riu Yamashita, Naoko Iida, Yasutoshii Sakamoto, Masayuki Hata, Hiroko Ichiki, Hiroshi Uchigata, Ryuta Mitani, Mayumi Fujita, Tomoe Murakami, Yui Ogata, Atsuko Shimizu, Izumi Miki, Satoshi Horasawa, Hiroki Sokuoka, Naomi Kuramoto, Megumi Futamura, Mihoko Yuasa, Yu Komura, Machiko Kumagami, Akio Dodo, Yuri Murata, Chiemi Notake, Mizuho Kikuchi, Yuko Oka, Yoshiko Onuma, Shiho Kanno
Translational Research Sample Management Office
Yoshikatsu Koga, Mari Takahashi, Yasuko Tada, Hitomi Nakai, Yumie Takeshima, Naoko Ozaki, Mana Shimamura, Fubuki Omoya, Tomomi Kitaoka, Eriko Tajima
Supportive and Palliative Care Research Support Office
Sadamoto Zenda, Yasuhito Kamizono, Tomoka Okano, Sanae Shimada, Marie Yokoyama
Perioperative Treatment Development Promotion Office
Shin Kobayashi
Hematological Treatment Development Promotion Office
Junichiro Yuda
International Research Promotion Office
Yoshiaki Nakamura, Mitsuho Imai, Machiko Kumagami
Department of Data Science
Data Science Office
Toshihiro Misumi, Yuriko Takeda, Motoko Suzuki, Tomomi Nishikawa, Hiromichi Kimura, Kouji Oba, Saori Mishima
Biostatistics Office
Masashi Wakabayashi, Yuriko Takeda, Motoko Suzuki, Tomomi Nishikawa, Hiromichi Kimura
The Team and What We Do
Division of Drug and Diagnostic Development Promotion
Translational Research Support Office
It mainly supports secretariat and data center operations of multicenter clinical research.
Translational Research Sample Management Office
Research specimens, primarily obtained from patients, are appropriately controlled through collection, processing, storage, and disposal.
Supportive and Palliative Care Research Support Office
It mainly supports research on supportive and palliative care.
Hematological Treatment Development Promotion Office
This office supports therapeutic development of drugs mainly related to hematology and oncology.
Perioperative Treatment Development Promotion Office
Primarily supports the development of treatments related to perioperative care.
International Research Promotion Office
Mainly supports the promotion of international research aimed at the development of pharmaceutical products and diagnostic agents.
Data Science Office
This office is responsible for data center operations for ARCAD-Asia.
Biostatistics Office
It mainly supports biostatistics for the Clinical Research Support Office
Research Activities
Support was provided for approximately 50 clinical studies. Large-scale multi-center collaborative studies included patient registrations of solid and hematological malignancies as follows: 2,768 cases in MONSTAR-SCREEN-2, 547 cases in SCRUM disease registry, 5,515 cases in GOZILA, 7,102 cases in CIRCULATE-Japan, 161 cases in COSMOS, and 212 cases in HM-SCREEN-2. There were 23 paper publications, including in Cancer Discovery, and 45 conference presentations. Utilizing the SCRUM-Japan platform, regulatory approvals were obtained for 4 new drugs and 2 diagnostic agents. For international expansion, LC-SCRUM-Asia Pacific (LC-SCRUM-AP) was established, and patient registration began in October 2022 from Taiwan, Thailand, and Malaysia. As of the end of March 2024, 285 cases have been registered from 4 facilities across these 3 countries. In ARCAD-Asia, individual subject data from 13 trials involving 4,173 cases were integrated. This was then combined with the ARCAD database operated by the French ARCAD Foundation and the U.S. Mayo Clinic, resulting in a comprehensive database of 63 trials with 45,224 cases.
Education
By fiscal year 2023, 11 staff members obtained the Genomic Medical Research Coordinator qualification, 1 obtained the Certified CRC qualification, 5 obtained the GCP Passport qualification, 1 obtained the IT Passport qualification, and 2 obtained the Level 2 Statistics Certification. Additionally, we implemented candidate selection using professional networks, resulting in the hiring of one staff member who already possessed the GCP Passport qualification. For retention management, we encouraged joining academic societies and obtaining qualifications and implemented the conversion of part-time staff to full-time positions to promote long-term employment.
Future Prospects
(1) Regarding LC-SCRUM-AP, in the fiscal year 2023, we visited Vietnam as a new participating country and initiated discussions about research participation. In the fiscal year 2024, we plan to continue discussions with Vietnam while expanding facilities in existing participating countries such as Taiwan, Thailand, and Malaysia. We are also considering Indonesia as a new participating country and are in discussion with relevant organizations.
(2) We launched MONSTAR-SCREEN-3 in fiscal year 2024 based on multi-omics data, including DNA/RNA analysis of tissues and blood, and spatial transcriptome analysis.
(3) The second phase of ARCAD-Asia has been launched in fiscal year 2024, and ARCAD-Gastric, which expands from colorectal cancer to gastric cancer, is scheduled to be fully operational.
(4) Since fiscal year 2023, we have been conducting joint research with the Tohoku Medical Megabank Organization titled "Development of molecular residual disease detection and early cancer detection methods using liquid biopsy multi-omics with artificial intelligence," aimed at developing MRD and MCED assays.
List of papers published in 2023
Journal
1. Ouchi A, Sadachi R, Hamaguchi T, Tsukamoto S, Shimada Y, Inomata M, Takii Y, Komori K, Shiomi A, Shiozawa M, Ohue M, Watanabe J, Ito M, Kawashima Y, Kobatake T, Souda H, Saida Y, Hashimoto T, Sano Y, Kanemitsu Y. Prognostic Relevance of Primary Tumor Sidedness in Early-stage Colorectal Cancer: An Integrated Analysis of 4 Randomized Controlled Trials (JCOG2003A). Annals of surgery, 279:283-289, 2024
2. Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. Journal for immunotherapy of cancer, 12:e008210, 2024
3. Ikenaga N, Hashimoto T, Mizusawa J, Kitabayashi R, Sano Y, Fukuda H, Nakata K, Shibuya K, Kitahata Y, Takada M, Kamei K, Kurahara H, Ban D, Kobayashi S, Nagano H, Imamura H, Unno M, Takahashi A, Yagi S, Wada H, Shirakawa H, Yamamoto N, Hirono S, Gotohda N, Hatano E, Nakamura M, Ueno M. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Japan Clinical Oncology Group study JCOG2202 (LAPAN study). BMC cancer, 24:231, 2024
4. Bando H, Tsukada Y, Kumagai S, Miyashita Y, Taketomi A, Yuki S, Komatsu Y, Akiyoshi T, Shinozaki E, Kanemitsu Y, Takashima A, Shiozawa M, Shiomi A, Yamazaki K, Matsuhashi N, Hasegawa H, Kato T, Oki E, Fukui M, Wakabayashi M, Fuse N, Nishikawa H, Ito M, Yoshino T . VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer. Gastrointestinal Oncology, 3:2024
5. Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA oncology, 10:95-102, 2024
6. Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T, Kawasaki T, Fujisawa T, Ueda Y, Okano S, Tahara M, Yamaguchi M. Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study. Journal of oncology pharmacy practice, 30:295-303, 2024
7. Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, Kuboki Y, Bando H, Kojima T, Iida N, Shibuki T, Imai M, Fujisawa T, Nagamine M, Sakamoto N, Kuwata T, Yoshino T, Shitara K. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science, 115:1622-1633, 2024
8. Okunaka M, Kotani D, Fujiwara H, Sato K, Fujiwara N, Mishima S, Sakashita S, Yoshino T, Fujita T, Kojima T. Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Therapeutic advances in medical oncology, 16:17588359241229432, 2024
9. Une N, Kobayashi S, Kitaguchi D, Sunakawa T, Sasaki K, Ogane T, Hayashi K, Kosugi N, Kudo M, Sugimoto M, Hasegawa H, Takeshita N, Gotohda N, Ito M. Intraoperative artificial intelligence system identifying liver vessels in laparoscopic liver resection: a retrospective experimental study. Surgical endoscopy, 38:1088-1095, 2024
10. Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clinical cancer research, 30:436-443, 2024
11. Koganemaru S, Fuchigami H, Yamashita H, Morizono C, Sunakawa H, Kawazoe A, Nakamura Y, Kuboki Y, Shitara K, Yano T, Doi T, Yasunaga M. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry. Clinical pharmacology and therapeutics, 115:62-70, 2024
12. Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. Future oncology (London, England), 20:393-407, 2024
13. Olsen S, Nakamura Y. Serial comprehensive genomic profiling by next-generation sequencing for patients with metastatic colorectal cancer. Cancer science, 115:321-323, 2024
14. Tabernero J, Yoshino T, Stintzing S, de Gramont A, Gibbs P, Jonker DJ, Nygren P, Papadimitriou C, Prager GW, Tell R, Lenz HJ. A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. Cancer research communications, 4:28-37, 2024
15. Augustyniak M, Lou E, Jacobs G, Fleming M, Marshall J, Coutinho A, Yoshino T. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers. Journal of cancer education, 39:118-125, 2024
16. Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. Targeted oncology, 19:59-69, 2024
17. Takahashi S, Bando H, Kinoshita I, Modi S, Tsurutani J, Bang YJ, Sato Y, Nakatani S, Lee C, Sugihara M, Okuda Y, Iwata H. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese journal of clinical oncology, 54:434-443, 2024
18. Okunaka M, Kotani D, Mishima S, Nakamura M, Kawazoe A, Bando H, Yoshino T, Shitara K. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. Integrative cancer therapies, 23:15347354231225962, 2024
19. Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, André T, de Gramont A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. European journal of cancer (Oxford, England : 1990), 199:113537, 2024
20. Bando H, Yamaguchi K, Mitani S, Sawada K, Mishima S, Komine K, Okugawa Y, Hosoda W, Ebi H. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science, 115:1014-1021, 2024
21. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. Clinical colorectal cancer, 23:147-159.e7, 2024
22. Ogata T, Narita Y, Oze I, Kumanishi R, Nakazawa T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Bando H, Taniguchi H, Kadowaki S, Ando M, Ito S, Tajika M, Muro K. Chronological improvement of survival in patients with advanced gastric cancer over 15 years. Therapeutic advances in medical oncology, 16:17588359241229428, 2024
23. Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nature medicine, 30:730-739, 2024
24. Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, O'neil BH, Herrero FR, Peeters M, Soeda J, Suh M, Reichert H, Mezzi K, Fryzek J, Chia V, Rehn M, Stintzing S. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European journal of cancer (Oxford, England : 1990), 202:113975, 2024
25. Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, Yoshino T. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nature reviews. Gastroenterology & hepatology, 21:444-455, 2024
26. Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nature reviews. Clinical oncology, 21:354-369, 2024
27. Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. Journal of clinical oncology, JCO2301326, 2024
28. Hashimoto T, Nakamura Y, Oki E, Kobayashi S, Yuda J, Shibuki T, Bando H, Yoshino T. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology, 29:495-511, 2024
29. Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, Shiozawa M, Esaki T, Izawa N, Takeuchi S, Bando H, Iwasa S, Hasegawa H, Yamaguchi T, Taniguchi H, Ushida Y, Oizaki T, Inoue C, Yoshino T. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF(V600E)-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical colorectal cancer, 23:174-182.e6., 2024
30. Kagoura M, Kobayashi S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone. European journal of surgical oncology, 50:107980, 2024
31. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future oncology (London, England), 20:653-663, 2024
32. Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Scientific reports, 14:5311, 2024
33. Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. Journal for immunotherapy of cancer, 12:e008409, 2024
34. Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, Yamaguchi K, Yamazaki K, Sunakawa Y, Kato T, Okano N, Taniguchi H, Sato T, Oki E, Nishina T, Komatsu Y, Matsuhashi N, Goto M, Yasui H, Ohtsubo K, Moriwaki T, Takahashi N, Horita Y, Boku S, Wakabayashi M, Ikeno T, Mitani R, Yuasa M, Yoshino T. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. JCO precision oncology, 7:e2200688, 2023
35. Ito S, Sano T, Mizusawa J, Tokunaga M, Hashimoto T, Imamura H, Teshima S, Nihei K, Yamada M, Choda Y, Imamura K, Hato S, Terashima M, Sasako M. Identifying Risk Factors of Complications following Total Gastrectomy for Gastric Cancer: Comparison between Splenectomy and Spleen-Preserving Surgery - A Supplementary Analysis of JCOG0110. Digestive surgery, 40:114-120, 2023
36. Yoshino T, Shi Q, Misumi T, Bando H, Wakabayashi M, Raeisi M, Andre T, de Gramont A. A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative. Nature medicine, 29:2389-2390, 2023
37. Hashimoto T, Otsu S, Hironaka S, Takashima A, Mizusawa J, Kataoka T, Fukuda H, Tsukamoto S, Hamaguchi T, Kanemitsu Y. Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future oncology (London, England), 19:1593-1600, 2023
38. Hashimoto T, Tsukada Y, Ito M, Kanato K, Mizusawa J, Fukuda H, Tsukamoto S, Takashima A, Kanemitsu Y. Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study). BMJ open, 13:e073217, 2023
39. Kobayashi S, Bando H, Taketomi A, Takamoto T, Shinozaki E, Shiozawa M, Hara H, Yamazaki K, Komori K, Matsuhashi N, Kato T, Kagawa Y, Yokota M, Oki E, Komine K, Takahashi S, Wakabayashi M, Yoshino T. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. BMC cancer, 23:779, 2023
40. Hashimoto T, Maruyama S, Takii Y, Mizusawa J, Kataoka T, Fukuda H, Tsukamoto S, Takashima A, Hamaguchi T, Kanemitsu Y. A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006. Future oncology (London, England), 19:1897-1904, 2023
41. Hashimoto T, Nakayama I, Ohashi M, Mizusawa J, Kawachi H, Kita R, Fukuda H, Kurokawa Y, Boku N, Yoshikawa T, Terashima M. Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer. Future oncology (London, England), 19:2147-2155, 2023
42. Miyoshi T, Ito H, Wakabayashi M, Hashimoto T, Sekino Y, Suzuki K, Tsuboi M, Moriya Y, Yoshino I, Isaka T, Hattori A, Mimae T, Isaka M, Maniwa T, Endo M, Yoshioka H, Nakagawa K, Nakajima R, Tsutani Y, Saji H, Okada M, Aokage K, Fukuda H, Watanabe SI. Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer. European journal of cardio-thoracic surgery, 64:ezad365, 2023
43. Hashimoto T, Tsukamoto S, Murofushi K, Ito Y, Hirano H, Tsukada Y, Sasaki K, Mizusawa J, Fukuda H, Takashima A, Kanemitsu Y. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010). BJS open, 7:zrad110, 2023
44. Takeda Y, Misumi T, Bando H, Suzuki M, Wakabayashi M, Oki E, Yamazaki K, Kakeji Y, Shitara K, Terashima M, Raeisi M, Maehara Y, Ohtsu A, Andre T, de Gramont A, Shi Q, Yoshino T . ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow. ESMO Gastrointestinal Oncology, 2:2023
45. Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. British journal of cancer, 128:1897-1905, 2023
46. Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA, 329:1271-1282, 2023
47. Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study). British journal of cancer, 129:1032-1039, 2023
48. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kagawa Y, Takahashi N, Denda T, Esaki T, Kawakami H, Satake H, Takashima A, Matsuhashi N, Kato T, Asano C, Abe Y, Nomura S, Yoshino T. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. Cancer medicine, 12:18702-18716, 2023
49. Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. British journal of cancer, 128:1603-1608, 2023
50. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer science, 114:2098-2108, 2023
51. Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer science, 114:4643-4653, 2023
52. Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors. International journal of clinical oncology, 28:827-840, 2023
53. Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. International journal of clinical oncology, 28:941-955, 2023
54. Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. International journal of clinical oncology, 28:1237-1258, 2023
55. Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, Sato J, Koyama T, Iwasa S, Sudo K, Kondo S, Yonemori K, Shitara K, Shiono S, Matsuoka D, Yasuda K, Otake Y, Suzuki T, Takase T, Takashima S, Yamaguchi K, Semba T, Yamamoto N. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications, 3:1189-1199, 2023
56. Sato M, Enokida T, Wada A, Okano S, Tanaka H, Fujisawa T, Ueda Y, Motegi A, Shinozaki T, Takeshita N, Tanaka N, Zenda S, Matsuura K, Akimoto T, Hayashi R, Tahara M. Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. International journal of clinical oncology, 28:1023-1032, 2023
57. Tanaka H, Enokida T, Okano S, Fujisawa T, Tanaka N, Takeshita N, Onaga R, Hoshi Y, Wada A, Sato M, Ueda Y, Tahara M. Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Frontiers in oncology, 13:1221352, 2023
58. Onaga R, Enokida T, Ito K, Ueda Y, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Takeshita N, Tanaka N, Hoshi Y, Tahara M. Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin. Frontiers in oncology, 13:1185198, 2023
59. Horinouchi A, Enokida T, Suzuki S, Kamata H, Kaneko A, Matsuyama C, Fujisawa T, Ueda Y, Ito K, Okano S, Kawasaki T, Tahara M. A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer. Frontiers in oncology, 13:1145323, 2023
60. Matsuyama C, Enokida T, Ueda Y, Suzuki S, Fujisawa T, Ito K, Okano S, Tahara M. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Frontiers in oncology, 13:1139659, 2023
61. Shibutani Y, Tajiri K, Suzuki S, Enokida T, Sagara A, Okano S, Fujisawa T, Sato F, Yumoto T, Sano M, Kawasaki T, Tahara M. Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer. Cancer medicine, 12:20773-20782, 2023
62. Takeshita N, Enokida T, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Tanaka N, Onaga R, Hoshi Y, Sakashita S, Ishii G, Tahara M. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Oral oncology, 147:106615, 2023
63. Ohtsu A, Goto K, Yoshino T. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 99:241-253, 2023
64. Kitaguchi D, Tsukada Y, Ito M, Horasawa S, Bando H, Yoshino T, Yamada K, Ajioka Y, Sugihara K. Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma. European journal of surgical oncology, 49:106929, 2023
65. Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, Yoshino T, Saji S, Matsuda F. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population. Cancer medicine, 12:7808-7814, 2023
66. Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nature reviews. Gastroenterology & hepatology, 20:306-322, 2023
67. Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, André T, Carrière Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer. Journal of clinical oncology, 41:2628-2637, 2023
68. Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, Yoshino T, Tsuchihara K. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. International journal of clinical oncology, 28:654-663, 2023
69. Aibe N, Ogino H, Wakatsuki M, Fujikawa K, Teramukai S, Fukumitsu N, Shiba S, Yamamoto N, Nomoto A, Ono T, Oguri M, Yamaguchi H, Numajiri H, Shibuya K, Okazaki S, Miyasaka Y, Okonogi N, Murata K, Tatebe H, Motegi A, Okimoto T, Yoshino T, Mandai M, Katoh N, Tsuji H, Sakurai H. Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy. Journal of radiation research, 64:i69-i83, 2023
70. Le DT, Diaz LA Jr, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil BH, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Élez E, Al-Batran SE, Boland PM, Cui Y, Leconte P, Marinello P, André T. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European journal of cancer (Oxford, England : 1990), 186:185-195, 2023
71. Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nature communications, 14:3332, 2023
72. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet (London, England), 402:41-53, 2023
73. Strickler JH, Yoshino T, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, Modest DP. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. The oncologist, 28:e981-e994, 2023
74. Funada S, Luo Y, Kataoka Y, Yoshioka T, Fujita Y, Yoshida S, Katsura M, Tada M, Nishioka N, Nakamura Y, Ueno K, Uozumi R, Furukawa TA. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study. BMJ evidence-based medicine, 28:372-382, 2023
75. Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, André T, Laurent-Puig P, Shi Q. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Annals of oncology, 34:1025-1034, 2023
76. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers, 15:4117, 2023
77. Okunaka M, Kawazoe A, Nakamura H, Kotani D, Mishima S, Kuboki Y, Nakamura Y, Shitara K. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Gastric cancer, 26:1030-1039, 2023
78. Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, Doi T, Yoshino T, Kuronita T, Elenbaas B, Wahra P, Zhang H, Crowley L, Jenkins MH, Clark A, Kojima T. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. Scientific reports, 13:16017, 2023
79. Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of clinical oncology, 41:5569-5578, 2023
80. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170. European journal of cancer (Oxford, England : 1990), 194:113339, 2023
81. Kajiwara T, Nishina T, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Yamamoto Y, Yamazaki K, Yoshino T, Hyodo I. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers, 15:5172, 2023
82. Caughey BA, Umemoto K, Green MF, Ikeda M, Lowe ME, Ueno M, Niedzwiecki D, Taniguchi H, Walden DJ, Komatsu Y, D'Anna R, Esaki T, Denda T, Datto MB, Bando H, Bekaii-Saab T, Yoshino T, Strickler JH, Nakamura Y. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas. Journal of gastrointestinal oncology, 14:2083-2096, 2023
83. Bando H, Tajima E, Aoyagi Y, Ng D, Mizuguchi K, Suzuki M, Takeda Y, Misumi T, Brown L, Murchison M, Lamba V, Zeng Y, Froment M, Jung J, Fedak K, Wang B, Yoshino T, Ohtsu A . The emerging role of real-world data in oncology care in Japan. ESMO Real World Data and Digital Oncology, 2:2023
84. Katada C, Yokoyama T, Hirasawa D, Iizuka T, Kikuchi D, Yano T, Hombu T, Yoshio T, Yoshimizu S, Ono H, Yabuuchi Y, Terai S, Hashimoto S, Takahashi K, Tanaka S, Urabe Y, Arima M, Tanabe S, Wada T, Furue Y, Oyama T, Takahashi A, Sakamoto Y, Muto M. Curative Management After Endoscopic Resection for Esophageal Squamous Cell Carcinoma Invading Muscularis Mucosa or Shallow Submucosal Layer-Multicenter Real-World Survey in Japan. The American journal of gastroenterology, 118:1175-1183, 2023
85. Shibuki T, Okumura K, Sekine M, Kobori I, Miyagaki A, Sasaki Y, Takano Y, Hashimoto Y. Covered self-expandable metallic stents versus plastic stents for endoscopic ultrasound-guided hepaticogastrostomy in patients with malignant biliary obstruction. Clinical endoscopy, 56:802-811, 2023
86. Satake T, Shibuki T, Watanabe K, Sasaki M, Imaoka H, Mitsunaga S, Kojima M, Ikeda M. Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Frontiers in oncology, 13:1234113, 2023
87. Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, Buck W, Besenhofer L, Boghaert E, Cheng D, Cojocari D, Doyle K, Hansen TM, Huang K, Johnson EF, Judd AS, Judge RA, Kalvass JC, Kunzer A, Lam LT, Li R, Martin RL, Mastracchio A, Mitten M, Petrich A, Wang J, Ward JE, Zhang H, Wang X, Wolff JE, Bell-McGuinn KM, Souers AJ. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Communications medicine, 3:154, 2023
88. Nakazawa J, Tsuruta N, Shimokawa M, Kawahira M, Arima S, Ido A, Koga F, Ueda Y, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Otsuka T, Shirakawa T, Mitsugi K. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Oncology, 101:22-31, 2023
89. Sekine M, Hashimoto Y, Shibuki T, Okumura K, Kobori I, Miyagaki A, Sasaki Y, Takano Y, Matsumoto K, Mashima H. A retrospective multicenter study comparing the punctures to B2 and B3 in endoscopic ultrasound-guided hepaticogastrostomy. DEN open, 3:e201, 2023
90. Ide Y, Otsuka T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Anticancer research, 43:1817-1826, 2023
91. Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. International journal of clinical oncology, 28:1073-1081, 2023
92. Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Scientific reports, 13:8815, 2023
93. Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Makiyama A, Taguchi H, Honda T, Ushijima T, Miwa K, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Scientific reports, 13:19399, 2023
94. Shibuki T, Sasaki M, Yamaguchi S, Inoue K, Taira T, Satake T, Watanabe K, Imaoka H, Mitsunaga S, Fujisawa T, Tomizawa K, Oyoshi H, Nakamura M, Hojo H, Ikeda M. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Radiation oncology (London, England), 18:199, 2023
95. Imai M, Nakamura Y, Denda T, Komatsu Y, Yuki S, Nishina T, Hamamoto Y, Hara H, Esaki T, Kawakami H, Kato K, Satoh T, Okano N, Sunakawa Y, Taniguchi H, Yamaguchi K, Yamada T, Miki I, Wakabayashi M, Kuwata T, Shitara K, Yoshino T . Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis. ESMO Gastrointestinal Oncology, 2:8-17, 2023
96. Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K, Oki E, Satoh T, Aoki D, Yamazaki K, Esaki T, Ueno M, Nishina T, Sunakawa Y, Denda T, Bando H, Kuramoto N, Horasawa S, Abutani H, Lee JK, Madison RW, Oxnard GR, Yoshino T. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. The Journal of Liquid Biopsy, 1:2023
97. Watanabe J, Kagawa Y, Chida K, Ando K, Kotani D, Oba K, Bando H, Hojo H, Shimamoto S, Sakashita S, Kuwata T, Tsuboyama T, Hosomi N, Uemura M, Uehara K, Ito M, Oki E, Takemasa I, Misugi E, Sledge G, Sumani K, Imoto S, Kato T, Yoshino T. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial. ESMO Gastrointestinal Oncology, 1:9-14, 2023